SCHEMBL6433486

SCHEMBL6433486

O=C(O)c1ccc2c(Cl)cnc(Cl)c2c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PLAU P00749 4/20 0.51
NAPRT Q6XQN6 1/20 0.50
TSHR P16473 2/20 0.48
PLG P00747 2/20 0.44
ALDH1A1 P00352 2/20 0.42
POLB P06746 1/20 0.42
HPGD P15428 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MAPT P10636 1/20 0.41
HTR5A P47898 1/20 0.40
SLC22A12 Q96S37 2/20 0.40
P4HA1 P13674 2/20 0.40
P4HTM Q9NXG6 1/20 0.40
TTR P02766 4/20 0.40
KMO O15229 1/20 0.40
SRD5A2 P31213 1/20 0.40
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6433263 0.86 PLAU (0.42) PLAUNAPRTPLGPOLBHTR5A
SCHEMBL13754214 0.85 ALDH1A1 (0.42) PLAUNAPRTPLGALDH1A1HPGD
SCHEMBL9907725 0.83 PLAU (0.49) PLAUNAPRTTSHRPLGALDH1A1
SCHEMBL27185299 0.83 NAPRT (0.47) NAPRTTSHRALDH1A1POLBHPGD
SCHEMBL17437241 0.80 PLAU (0.49) PLAUNAPRTTSHRPLGALDH1A1
SCHEMBL9907716 0.80 PLAU (0.52) PLAUNAPRTTSHRPLGALDH1A1
SCHEMBL4991890 0.78 TSHR (0.50) NAPRTTSHRALDH1A1POLBL3MBTL1
SCHEMBL9907662 0.77 HTR5A (0.56) PLAUNAPRTTSHRPLGHTR5A
SCHEMBL6437644 0.77 ALDH1A1 (0.53) ALDH1A1POLBHPGDL3MBTL1MAPT
Hydrochloric Acid SCHEMBL10456360 0.77 TSHR (0.48) NAPRTTSHRALDH1A1POLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed
EP-1077945-A1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2001-02-28 EP disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed
WO-2000005214-A2 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 PLAU 119/4885NAPRT 2404/4885TSHR 4346/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 PLAU 119/4885NAPRT 2404/4885TSHR 4346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.